Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development and Evaluation of a Novel Hyaluronic Acid and Chitosan-modified Phytosome for Co-delivery of Oxymatrine and Glycyrrhizin for Combination Therapy

Author(s): Xiaojin Chen, Shuying Yu, Pingping Wang, XinFeng Zhao and Gao Sang*

Volume 19, Issue 2, 2024

Published on: 10 March, 2023

Page: [154 - 164] Pages: 11

DOI: 10.2174/1574892818666230215112942

Price: $65

Abstract

Background: Multidrug resistance (MDR) of cancer cells is a major obstacle to efficient cancer chemotherapy. Combination therapy is expected to enhance the anticancer effect and reverse MDR. Numerous patents involve different kinds of nanoparticles for the co-delivery of multiple chemotherapeutics, but the FDA has approved none.

Objective: In this study, oxymatrine (OMT) and glycyrrhizin (GL) were co-loaded into phytosomes as the core of nanocarriers, and the shell was cross-linked with chitosan (CS) and hyaluronic acid (HA) with the capability for the controlled, sequential release and the targeted drug uptake.

Methods: Phospholipid complexes of OMT and GL (OGPs) were prepared by a solvent evaporation technique and could self-assemble in an aqueous solution to form phytosomes. CS and HA were sequentially coated on the surface of OGPs via electrostatic interactions to obtain CS coated OGPs (CS-OGPs) and HA modified CS-OGPs (HA-CS-OGPs), respectively. The particle size and zeta potential were measured to optimize the formulations. In vitro cytotoxicity and cellular uptake experiments on HepG2 cells were performed to evaluate the anticancer activity.

Results: OGPs were obtained with nano-size around 100 nm, and CS and HA coating on phytosomes could change the particle size and surface potential. The drug loading of OMT and GL showed that the nanocarriers could maintain a fixed ratio of 1:1. The in vitro release experiments indicated the release of OMT and GL was pH-dependent and sequential: the release of OMT from CS-OGPs and HA-CS-OGPs was significantly increased at pH 5.0 compared to the release at pH 7.4, while GL exhibited sustained released from CS-OGPs and HA-CS-OGPs at pH 5.0. Furthermore, in vitro cytotoxicity and cellular uptake experiments on HepG2 cells demonstrated that the co-delivery system based on phytosomes had significant synergistic anti-tumor activities, and the effects were enhanced by CS and HA modification.

Conclusion: The delivery of OMT and GL via HA-CS-OGPs might be a promising treatment to reverse MDR in cancer therapy.

« Previous Next »
[1]
Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer 2016; 122(22): 3430-46.
[http://dx.doi.org/10.1002/cncr.30237] [PMID: 27622302]
[2]
Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer 2020; 1873(1): 188314.
[http://dx.doi.org/10.1016/j.bbcan.2019.188314] [PMID: 31682895]
[3]
Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019; 156(2): 477-491.e1.
[http://dx.doi.org/10.1053/j.gastro.2018.08.065] [PMID: 30367835]
[4]
He Q, Guo P, Bo Z, et al. Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma. Cancer Cell Int 2022; 22(1): 249.
[http://dx.doi.org/10.1186/s12935-022-02643-6] [PMID: 35945536]
[5]
Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC transporters: Regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma. Curr Med Chem 2019; 26(7): 1224-50.
[http://dx.doi.org/10.2174/0929867325666180105103637] [PMID: 29303075]
[6]
Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy- Strategies and perspectives. J Control Release 2016; 240: 489-503.
[http://dx.doi.org/10.1016/j.jconrel.2016.06.012] [PMID: 27287891]
[7]
Gurunathan S, Kang MH, Qasim M, Kim JH. Nanoparticle-mediated combination therapy: Two-in-one approach for cancer. Int J Mol Sci 2018; 19(10): 3264.
[http://dx.doi.org/10.3390/ijms19103264] [PMID: 30347840]
[8]
Shenqian GY. Targeted drug co-delivery nano system, and preparation method and application thereof. CN113018453 (A), 2021.
[9]
Limei HLZJS. Nano co-delivery of quercetin and alantolactone promotes anti-tumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer. US2022211663 (A1), 2022.
[10]
Liu W, Zhao X, Chen Q, et al. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int J Nanomedicine 2014; 10: 257-70.
[http://dx.doi.org/10.2147/IJN.S73322] [PMID: 25565818]
[11]
Wang Shubin L, Yu Zhu. Tumor microenvironment responsetype nano-composite drug loading system, and preparation method therefor and use thereof. WO2021226762 (A1), 2021.
[12]
Zhu N, Hou J. Molecular mechanism of the anti-inflammatory effects of Sophorae Flavescentis Aiton identified by network pharmacology. Sci Rep 2021; 11(1): 1005.
[http://dx.doi.org/10.1038/s41598-020-80297-y] [PMID: 33441867]
[13]
Shen H, Qu Z, Harata-Lee Y, et al. Understanding the mechanistic contribution of herbal extracts in compound kushen injection with transcriptome analysis. Front Oncol 2019; 9: 632.
[http://dx.doi.org/10.3389/fonc.2019.00632] [PMID: 31380274]
[14]
Cui J, Qu Z, Harata-Lee Y, et al. The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms. PLoS One 2020; 15(7): e0236395.
[http://dx.doi.org/10.1371/journal.pone.0236395] [PMID: 32730293]
[15]
Gao L, Wang K, Zhou Y, Fang J, Qin X, Du G. Uncovering the anticancer mechanism of compound kushen injection against HCC by integrating quantitative analysis, network analysis and experimental validation. Sci Rep 2018; 8(1): 624.
[http://dx.doi.org/10.1038/s41598-017-18325-7] [PMID: 29330507]
[16]
Yang Y, Sun M, Li W, et al. Rebalancing TGF‐β/Smad7 signaling via Compound kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis. Clin Transl Med 2021; 11(7): e410.
[http://dx.doi.org/10.1002/ctm2.410] [PMID: 34323416]
[17]
Ma X, Li RS, Wang J, et al. The therapeutic efficacy and safety of compound kushen injection combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: an update systematic review and meta-analysis. Front Pharmacol 2016; 7: 70.
[http://dx.doi.org/10.3389/fphar.2016.00070] [PMID: 27065861]
[18]
Wang W, You R, Qin W, et al. Anti-tumor activities of active ingredients in compound kushen injection. Acta Pharmacol Sin 2015; 36(6): 676-9.
[http://dx.doi.org/10.1038/aps.2015.24] [PMID: 25982630]
[19]
Liu Y, Xu Y, Ji W, et al. Anti-tumor activities of matrine and oxymatrine: literature review. Tumour Biol 2014; 35(6): 5111-9.
[http://dx.doi.org/10.1007/s13277-014-1680-z] [PMID: 24526416]
[20]
Chen K, Zhu P, Ye J, et al. Oxymatrine inhibits the migration and invasion of hepatocellular carcinoma cells by reducing the activity of MMP-2/-9 via regulating p38 signaling pathway. J Cancer 2019; 10(22): 5397-403.
[http://dx.doi.org/10.7150/jca.32875] [PMID: 31632484]
[21]
Goncalves BM, Cardoso DS, Ferreiro MJ. Overcoming multidrug resistance: Flavonoid and terpenoid nitrogen-containing derivatives as ABC transporter modulators. Molecules 2020; 25(25(15): 3364.
[http://dx.doi.org/10.3390/molecules25153364] [PMID: 32722234]
[22]
Tinoush B, Shirdel I, Wink M. Phytochemicals: Potential lead molecules for MDR reversal. Front Pharmacol 2020; 11: 832.
[http://dx.doi.org/10.3389/fphar.2020.00832] [PMID: 32636741]
[23]
Zhang Y, Liang Y, He C. Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine. Chin Med 2017; 12(1): 20.
[http://dx.doi.org/10.1186/s13020-017-0140-2] [PMID: 28702078]
[24]
Selyutina OY, Polyakov NE. Glycyrrhizic acid as a multifunctional drug carrier - From physicochemical properties to biomedical applications: A modern insight on the ancient drug. Int J Pharm 2019; 559: 271-9.
[http://dx.doi.org/10.1016/j.ijpharm.2019.01.047] [PMID: 30690130]
[25]
Selyutina OY, Polyakov NE, Korneev DV, Zaitsev BN. Influence of glycyrrhizin on permeability and elasticity of cell membrane: perspectives for drugs delivery. Drug Deliv 2016; 23(3): 848-55.
[http://dx.doi.org/10.3109/10717544.2014.919544] [PMID: 24870200]
[26]
Kim M, Park SC, Lee DY. Glycyrrhizin as a nitric oxide regulator in cancer chemotherapy. Cancers 2021; 13(22): 5762.
[http://dx.doi.org/10.3390/cancers13225762] [PMID: 34830916]
[27]
He Y, Wei Z, Xie Y, et al. Potential synergic mechanism of Wutou-Gancao herb-pair by inhibiting efflux transporter P-glycoprotein. J Pharm Anal 2020; 10(2): 178-86.
[http://dx.doi.org/10.1016/j.jpha.2019.09.004] [PMID: 32373389]
[28]
Shi H, Song H, Gao Q, Si J, Zou Q. Combination of oxymatrine and diammonium glycyrrhizinate significantly mitigates mice allergic contact dermatitis induced by dinitrofluorobenzene. Exp Biol Med (Maywood) 2019; 244(13): 1111-9.
[http://dx.doi.org/10.1177/1535370219864895] [PMID: 31342769]
[29]
Lu M, Qiu Q, Luo X, et al. Phyto-phospholipid complexes (phytosomes): A novel strategy to improve the bioavailability of active constituents. Asian J Pharma Sci 2019; 14(3): 265-74.
[http://dx.doi.org/10.1016/j.ajps.2018.05.011] [PMID: 32104457]
[30]
Kuche K, Bhargavi N, Dora CP, Jain S. Drug-phospholipid complex-a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech 2019; 20(2): 43.
[http://dx.doi.org/10.1208/s12249-018-1252-4] [PMID: 30610392]
[31]
Xuejun LYL. Flavonoid polyphenol drug self-emulsifying composition, preparation method therefor, pharmaceutical composition thereof and application thereof. US2022168237 (A1) 2022.
[32]
Mikušová V, Mikuš P. Advances in chitosan-based nanoparticles for drug delivery. Int J Mol Sci 2021; 22(17): 9652.
[http://dx.doi.org/10.3390/ijms22179652] [PMID: 34502560]
[33]
Dhar D, Antonucci L, Nakagawa H, et al. Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. Cancer Cell 2018; 33(6): 1061-77.
[http://dx.doi.org/10.1016/j.ccell.2018.05.003] [PMID: 29894692]
[34]
Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: Therapeutic implications. J Hematol Oncol 2018; 11(1): 64.
[http://dx.doi.org/10.1186/s13045-018-0605-5] [PMID: 29747682]
[35]
Wang T, Hou J, Su C, Zhao L, Shi Y. Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44. J Nanobiotechnology 2017; 15(1): 7.
[http://dx.doi.org/10.1186/s12951-016-0245-2] [PMID: 28068992]
[36]
Yang L, Gao S, Asghar S, et al. Hyaluronic acid/chitosan nanoparticles for delivery of curcuminoid and its in vitro evaluation in glioma cells. Int J Biol Macromol 2015; 72: 1391-401.
[http://dx.doi.org/10.1016/j.ijbiomac.2014.10.039] [PMID: 25450553]
[37]
Suh MS, Shen J, Kuhn LT, Burgess DJ. Layer-by-layer nanoparticle platform for cancer active targeting. Int J Pharm 2017; 517(1-2): 58-66.
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.006] [PMID: 27923697]
[38]
Xu Y, Asghar S, Yang L, et al. Nanoparticles based on chitosan hydrochloride/hyaluronic acid/PEG containing curcumin: In vitro evaluation and pharmacokinetics in rats. Int J Biol Macromol 2017; 102: 1083-91.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.04.105] [PMID: 28472690]
[39]
Haenisch S, Laechelt S, Bruckmueller H, et al. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol Pharmacol 2011; 80(2): 314-20.
[http://dx.doi.org/10.1124/mol.110.070714] [PMID: 21540293]
[40]
Chen D, Pan X, Xie F, et al. Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles. Int J Nanomedicine 2018; 13: 6855-70.
[http://dx.doi.org/10.2147/IJN.S181928] [PMID: 30498347]
[41]
Yu F, Huang J, Yu Y, et al. Glutathione-responsive multilayer coated gold nanoparticles for targeted gene delivery. J Biomed Nanotechnol 2016; 12(3): 503-15.
[http://dx.doi.org/10.1166/jbn.2016.2177] [PMID: 27280248]
[42]
Ma Y, Zhou H, Hu F, et al. Multifunctional nanogel engineering with redox-responsive and AIEgen features for the targeted delivery of doxorubicin hydrochloride with enhanced antitumor efficiency and real-time intracellular imaging. Artif Cells Nanomed Biotechnol 2018; 46(sup3): S900-10.
[http://dx.doi.org/10.1080/21691401.2018.1518910]
[43]
Diao L, Shen A, Yang Y, Tao J, Hu Y. CD44-targeted hyaluronic acid-curcumin reverses chemotherapeutics resistance by inhibiting P-gp and anti-apoptotic pathways. RSC Advances 2019; 9(70): 40873-82.
[http://dx.doi.org/10.1039/C9RA08202F] [PMID: 35540044]
[44]
Kalam MA. Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone. Int J Biol Macromol 2016; 89: 127-36.
[http://dx.doi.org/10.1016/j.ijbiomac.2016.04.070] [PMID: 27126165]
[45]
Wang H, Cui Y, Fu Q, et al. A phospholipid complex to improve the oral bioavailability of flavonoids. Drug Dev Ind Pharm 2015; 41(10): 1693-703.
[http://dx.doi.org/10.3109/03639045.2014.991402] [PMID: 25496311]
[46]
Song Z, Yin J, Xiao P, et al. Improving breviscapine oral bioavailability by preparing nanosuspensions, liposomes and phospholipid complexes. Pharmaceutics 2021; 13(2): 132.
[http://dx.doi.org/10.3390/pharmaceutics13020132] [PMID: 33498470]
[47]
Alhakamy NA, A. Fahmy U, Badr-Eldin SM, et al. Optimized icariin phytosomes exhibit enhanced cytotoxicity and apoptosis-inducing activities in ovarian cancer cells. Pharmaceutics 2020; 12(4): 346.
[http://dx.doi.org/10.3390/pharmaceutics12040346] [PMID: 32290412]
[48]
Barani M, Sangiovanni E, Angarano M, et al. Phytosomes as innovative delivery systems for phytochemicals: a comprehensive review of literature. Int J Nanomedicine 2021; 16: 6983-7022.
[http://dx.doi.org/10.2147/IJN.S318416] [PMID: 34703224]
[49]
Kang BS, Choi JS, Lee SE, et al. Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles. Carbohydr Polym 2017; 159: 39-47.
[http://dx.doi.org/10.1016/j.carbpol.2016.12.009] [PMID: 28038752]
[50]
Abd El Hady WE, Mohamed EA, Soliman OAEA. EL Sabbagh HM. in vitro-in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin. Int J Nanomedicine 2019; 14: 7191-213.
[http://dx.doi.org/10.2147/IJN.S213836] [PMID: 31564873]
[51]
Vieira ACC, Chaves LL, Pinheiro S, et al. Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis. Int J Pharm 2018; 536(1): 478-85.
[http://dx.doi.org/10.1016/j.ijpharm.2017.11.071] [PMID: 29203137]
[52]
Nokhodi F, Nekoei M, Goodarzi MT. Hyaluronic acid-coated chitosan nanoparticles as targeted-carrier of tamoxifen against MCF7 and TMX-resistant MCF7 cells. J Mater Sci Mater Med 2022; 33(2): 24.
[http://dx.doi.org/10.1007/s10856-022-06647-6] [PMID: 35157166]
[53]
Telange DR, Patil AT, Pethe AM, Fegade H, Anand S, Dave VS. Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential. Eur J Pharm Sci 2017; 108: 36-49.
[http://dx.doi.org/10.1016/j.ejps.2016.12.009] [PMID: 27939619]
[54]
Xie J, Li Y, Song L, Pan Z, Ye S, Hou Z. Design of a novel curcumin-soybean phosphatidylcholine complex-based targeted drug delivery systems. Drug Deliv 2017; 24(1): 707-19.
[http://dx.doi.org/10.1080/10717544.2017.1303855] [PMID: 28436718]
[55]
Yilmaz MD. Layer-by-layer hyaluronic acid/chitosan polyelectrolyte coated mesoporous silica nanoparticles as pH-responsive nanocontainers for optical bleaching of cellulose fabrics. Carbohydr Polym 2016; 146: 174-80.
[http://dx.doi.org/10.1016/j.carbpol.2016.03.037] [PMID: 27112863]
[56]
Wu Y, Wu J, Cao J, et al. Facile fabrication of poly(acrylic acid) coated chitosan nanoparticles with improved stability in biological environments. Eur J Pharm Biopharm 2017; 112: 148-54.
[http://dx.doi.org/10.1016/j.ejpb.2016.11.020] [PMID: 27890571]
[57]
Chakraborty K, Tripathi A, Mishra S, Mallick AM, Roy RS. Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment. Biosci Rep 2022; 42(7): BSR20212051.
[http://dx.doi.org/10.1042/BSR20212051] [PMID: 35638450]
[58]
in vitro Co-delivery evaluation of novel pegylated nano-liposomal herbal drugs of silibinin and glycyrrhizic acid (nano-phytosome) to hepatocellular carcinoma cells. Cell J 2016; 18(2): 135-48.
[59]
Dora CP, Kushwah V, Katiyar SS, et al. Improved metabolic stability and therapeutic efficacy of a novel molecular gemcitabine phospholipid complex. Int J Pharm 2017; 530(1-2): 113-27.
[http://dx.doi.org/10.1016/j.ijpharm.2017.07.060] [PMID: 28739504]
[60]
Xu L, Xu D, Li Z, Gao Y, Chen H. Synthesis and potent cytotoxic activity of a novel diosgenin derivative and its phytosomes against lung cancer cells. Beilstein J Nanotechnol 2019; 10: 1933-42.
[http://dx.doi.org/10.3762/bjnano.10.189] [PMID: 31598460]
[61]
Salatin S, Yari Khosroushahi A. Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles. J Cell Mol Med 2017; 21(9): 1668-86.
[http://dx.doi.org/10.1111/jcmm.13110] [PMID: 28244656]
[62]
Yee Kuen C, Masarudin MJ. Chitosan nanoparticle-based system: A new insight into the promising controlled release system for lung cancer treatment. Molecules 2022; 27(2): 473.
[http://dx.doi.org/10.3390/molecules27020473] [PMID: 35056788]
[63]
Zhang X, Yang X, Ji J, Liu A, Zhai G. Tumor targeting strategies for chitosan-based nanoparticles. Colloids Surf B Biointerfaces 2016; 148: 460-73.
[http://dx.doi.org/10.1016/j.colsurfb.2016.09.020] [PMID: 27665379]
[64]
Aibani N, Rai R, Patel P, Cuddihy G, Wasan EK. Chitosan nanoparticles at the biological interface: Implications for drug delivery. Pharmaceutics 2021; 13(10): 1686.
[http://dx.doi.org/10.3390/pharmaceutics13101686] [PMID: 34683979]
[65]
Qiu L, Xu J, Ahmed KS, et al. Stimuli-responsive, dual-function prodrug encapsulated in hyaluronic acid micelles to overcome doxorubicin resistance. Acta Biomater 2022; 140: 686-99.
[http://dx.doi.org/10.1016/j.actbio.2021.11.050] [PMID: 34875359]
[66]
Zhang J, Song J, Liang X, et al. Hyaluronic acid-modified cationic nanoparticles overcome enzyme CYP1B1-mediated breast cancer multidrug resistance. Nanomedicine (Lond) 2019; 14(4): 447-64.
[http://dx.doi.org/10.2217/nnm-2018-0244] [PMID: 30694105]
[67]
Yang H, Wang N, Mo L, et al. Reduction sensitive hyaluronan-SS-poly(ε-caprolactone) block copolymers as theranostic nanocarriers for tumor diagnosis and treatment. Mater Sci Eng C 2019; 98: 9-18.
[http://dx.doi.org/10.1016/j.msec.2018.12.132] [PMID: 30813097]
[68]
Kesharwani P, Chadar R, Sheikh A, Rizg WY, Safhi AY. CD44-targeted nanocarrier for cancer therapy. Front Pharmacol 2022; 12: 800481.
[http://dx.doi.org/10.3389/fphar.2021.800481] [PMID: 35431911]
[69]
Badwaik V, Liu L, Gunasekera D, et al. Mechanistic insight into receptor-mediated delivery of cationic-beta-cyclodex trin: Hyaluronic acid-adamantamethamidyl host: Guest pDNA nanoparticles to CD44(+) Cells. Mol Pharm 2016; 13(3): 1176-84.
[70]
Spadea A, Rios de la Rosa JM, Tirella A, et al. Evaluating the efficiency of hyaluronic acid for tumor targeting via CD44. Mol Pharm 2019; 16(6): 2481-93.
[http://dx.doi.org/10.1021/acs.molpharmaceut.9b00083] [PMID: 31013093]
[71]
Kwon MY, Wang C, Galarraga JH, Puré E, Han L, Burdick JA. Influence of hyaluronic acid modification on CD44 binding towards the design of hydrogel biomaterials. Biomaterials 2019; 222: 119451.
[http://dx.doi.org/10.1016/j.biomaterials.2019.119451] [PMID: 31480001]
[72]
Almalik A, Donno R, Cadman CJ, Cellesi F, Day PJ, Tirelli N. Hyaluronic acid-coated chitosan nanoparticles: Molecular weight-dependent effects on morphology and hyaluronic acid presentation. J Control Release 2013; 172(3): 1142-50.
[http://dx.doi.org/10.1016/j.jconrel.2013.09.032] [PMID: 24103813]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy